Jasper Therapeutics, Inc.
JSPRHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Jasper Therapeutics, Inc. focuses on Biotechnology services and products. Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. The company carries a $17.0M market cap, placing it firmly in the micro-cap category. It is advancing a pipeline of medicines, including KP-104, a dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other unmet need nephrology disorders; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders.
Market Cap
$17.0M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-0.72
EPS (TTM)
$-1.04
EPS (Fwd)
$-0.70
ROE
—
ROA
—
Cash
—
Total Debt
—
Free CF
—
52W Change
-78.1%
Annual Financials
Cash vs Debt
Where JSPR stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, JSPR finished 34.25% below its 150-day moving average ($0.73) and 47.25% below its 200-day moving average ($0.91). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is JSPR overbought or oversold?
At the October 20, 2026 close, JSPR's RSI(14) was 29.0, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Investors considering Jasper Therapeutics, Inc. should weigh the typical risks associated with JSPR's sector, size, and financial profile against their own risk tolerance and investment objectives. No single metric tells the full story. Reviewing JSPR's risk profile alongside its fundamentals and technical indicators provides a more complete picture.